EMEA-002029-PIP01-16-M03

First published: 18/09/2023
EMA/697759/2022

Active substance	Tremelimumab
Therapeutic area	Oncology
Decision number	P/0367/2022
PIP number	EMEA-002029-PIP01-16-M03
Pharmaceutical form(s)	Concentrate for solution for infusion
Condition(s) / indication(s)	Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue) Treatment of malignant neoplasms of lymphoid tissue
Route(s) of administration	Intravenous use
Contact for public enquiries	AstraZeneca AB Tel. +46 8553 27591 E-mail: paediatrics@astrazeneca.com
Decision type	PM: decision on the application for modification of an agreed PIP